Brexit and Parallel Imports—the end of an era?

A Pricentric Brief by Sean Skulski "In short, parallel imports of medicines into the UK provide both certainty of supply, when there is not enough UK stock (because of a sudden spike in demand), and incentivized purchasing competition which saves the NHS over £100m per annum, on current estimates."  - Healthcare Distribution Association UK Council (2016) The United Kingdom has

Read More

Navigating HTA: AstraZeneca’s Fasenra and NICE

A Pricentric Brief by Sean Skulski According to the World Health Organization (WHO), Health Technology Assessment (HTA) is a multidisciplinary, systematic evaluation of the properties, effects, and/or impacts of health technology to inform a policy decision making. During HTA, authorities evaluate the social, economic, organization, and ethical issues of a health intervention or health technology. When a manufacturer is seeking approval

Read More

The Effect of Reference Pricing in the Gulf Central Committee Countries

A Pricentric Brief by Sean Skulski Background of the GCC-DR As the price for pharmaceuticals continued to rise, the Gulf countries sought to harmonize efforts to control costs. Formed in May 1999, the Gulf Central Committee for Drug Registration (GCC-DR) aimed to provide Gulf countries with safe and effective medicines at reasonable, more affordable prices. Initially, the GCC-DR consisted of

Read More

Contact Alliance